AARD

Aardvark is a clinical-stage pharmaceutical with zero product revenue (FY2025 revenue $0.00) whose entire value rests on preclinical and clinical programs whose status, data, and probability of success are not quantified anywhere in the provided filing excerpts. The 10-K's forward-looking section is a wall of boilerplate about 'the initiation, timing, progress, status and results of our preclinical studies, clinical trials,' the 'likelihood of our clinical trials demonstrating safety and efficacy,' and 'the timing or likelihood of regulatory filings and approval' — every one of these is an admitted uncertainty, and none resolves into a disclosed readout, indication, or catalyst date I can underwrite. That is the definition of unknowable risk: the asset value lives in data I do not have.

The numbers describe a company spending aggressively into that uncertainty. R&D leapt +181.8% to $48.9M, driving operating income to -$62.7M and net loss to -$57.6M (nearly tripling FY2024's -$20.6M loss). Operating cash flow swung to -$54.2M. Against that burn, cash is only $47.1M and actually fell 23.7% year-over-year. The saving grace is the rest of the balance sheet: total current assets of $112M (the ~$65M gap above cash is presumably marketable securities from a recent raise that lifted equity +295.1% to $107M), against just $10.5M of current liabilities — liabilities/equity of 0.10x and essentially no debt. So near-term solvency is fine, perhaps ~2 years of runway, but at this burn the company will need to raise again before any product economics exist, and that means dilution on a tiny 21.8M-share base.